Microbiome Therapeutics Market Size, Share & Forecast 2026-2035
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 1.1 billion
Estimated Base Value
2035 Forecast
US$ 15.2 billion
Projected Market Value
CAGR 2026–2035
30.0%
Compound Annual Growth
Largest Segment
Live Biotherapeutic Products
Fastest Growing Segment
Prebiotics
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
40.0% market share
Key Players
Seres Therapeutics
Emerging Players
Synlogic, Assembly Biosciences
Market Definition & Overview
The Microbiome Therapeutics Market encompasses the research, development, manufacturing, and commercialization of pharmaceutical products designed to modulate or restore the human microbiota for the prevention and treatment of diseases. This market primarily focuses on therapies targeting the gut microbiome, leveraging advanced biotechnology and biotics principles. It includes live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), and novel microbiome-modulating agents aimed at addressing conditions like gastrointestinal disorders, infectious diseases, metabolic syndromes, and neurological conditions, driving innovation in precision medicine within the 2026-2035 forecast period.
Scope
- Global market analysis across key geographies.
- Focus on therapeutic applications of microbiome modulation in humans.
- Segmentation by product type, application, and disease indication.
- Market forecast and analysis covering the period from 2026 to 2035.
Inclusions
- Live Biotherapeutic Products (LBPs) for human disease treatment.
- Fecal Microbiota Transplantation (FMT) therapies and related products.
- Engineered microbial consortia and synthetic biology-based microbiome therapeutics.
- Pharma-grade prebiotics and probiotics with specific therapeutic indications.
- Drug discovery, development, and clinical trials for microbiome-based drugs.
- Delivery platforms for targeted microbiome modulation in humans.
Exclusions
- Conventional small molecule or biologic drugs not related to microbiome modulation.
- Over-the-counter dietary supplements and functional foods lacking specific therapeutic claims.
- Diagnostic tests not directly integrated with microbiome therapeutic development or patient selection.
- Cosmetics, personal care products, or non-therapeutic nutraceuticals utilizing microbiome ingredients.
- Veterinary or agricultural applications of microbiome technology.
Market Size Forecast
Executive Summary
• The Microbiome Therapeutics market is valued at $1.1 Bn in 2025 and is forecast to reach $15.2 Bn by 2035, reflecting a robust CAGR of 30.0% as demand accelerates across every major segment and region over the ten-year outlook.
• Live Biotherapeutic Products leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 35.0%, while Emerging Areas is expanding the fastest at a 9.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 40.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Early-stage M&A activities and strategic alliances are accelerating, signaling a maturing competitive landscape and consolidation pressures among niche players seeking broader pipelines and market access, particularly in Western markets.
• Advancements in synthetic biology and AI-driven precision microbiome modulation are rapidly redefining therapeutic potential, pushing the boundaries of clinical trial design and accelerating product development timelines across diverse indications globally.
• Evolving global regulatory frameworks, especially expedited pathways for novel biotics, are significantly de-risking investment and fostering faster market entry, driving heightened interest from pharmaceutical giants seeking innovative treatment modalities.
• Significant venture capital inflows and public-private partnerships are primarily channeling into targeted therapeutic areas like GI disorders and oncology, spurring intensive R&D and specialized pipeline development within leading biotechnology hubs.
• The transition from preclinical research to scalable commercialization strategies is a critical hurdle, with regional variances in healthcare infrastructure and patient adoption influencing market penetration and long-term sustainability efforts.
• Developing robust and scalable manufacturing capabilities for live biotherapeutic products remains a pivotal challenge, necessitating strategic partnerships and advanced bioprocessing innovations to meet future demand and ensure product integrity.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Projection
The Microbiome Therapeutics Market, valued at $1.1 billion in the base year, is projected to surge to $15.2 billion by 2035.
Remarkable CAGR
This substantial market expansion is propelled by a remarkable Compound Annual Growth Rate (CAGR) of 30.0% between the base year and 2035.
Future Valuation
Achieving a valuation of $15.2 billion by 2035 underscores the significant future importance and market presence of microbiome-based therapeutics.
Live Biotherapeutics Lead
Live Biotherapeutic Products (LBPs) are poised to lead market growth, driven by extensive R&D and expanding clinical applications in various therapeutic areas.
Personalized Therapy Focus
A key trend involves the accelerating development of personalized microbiome-based therapies, offering highly targeted and effective treatments through advanced diagnostics.
Attractive Investment Landscape
The robust projected growth and substantial market size position the microbiome therapeutics sector as an attractive investment landscape within biotechnology and biotics industries.
Market Dynamics
Market Trends
- Personalized microbiome therapies are gaining traction.
- AI and machine learning adoption for drug discovery is rising.
- Live biotherapeutic products (LBPs) are becoming prominent.
- Interest in phage therapies and FMT continues to grow.
Growth Drivers
- Increasing prevalence of chronic diseases fuels demand.
- Significant R&D investments propel market growth.
- Growing understanding of the gut-brain axis is a key driver.
- Favorable regulatory pathways accelerate product development.
Restraints
- Stringent regulatory pathways hinder market entry for novel therapies.
- Manufacturing complexities pose significant challenges for consistent product quality.
- High R&D costs and lengthy clinical trials strain financial resources.
- Limited understanding of microbiome mechanisms creates development uncertainties.
Opportunities
- New therapies for challenging diseases offer significant potential.
- Expanding applications beyond the gut represent growth.
- Strategic partnerships can unlock new therapeutic avenues.
- Untapped emerging markets provide expansion opportunities.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Live Biotherapeutic ProductsFecal Microbiota TransplantationPrebioticsProbioticsPostbioticsPhage TherapyGene-Edited Microbiome TherapiesSmall Molecule Modulators |
| By Application | Infectious DiseasesInflammatory Bowel DiseaseMetabolic DisordersGastrointestinal DisordersOncologyNeurological DisordersAutoimmune DiseasesAllergies and Asthma |
| By Technology | Microbial CulturingHigh-Throughput SequencingBioinformatics and AIGene EditingFecal EncapsulationDrug Delivery SystemsSynthetic BiologyOmics Technologies |
| By End-User | HospitalsClinicsAcademic and Research InstitutionsPharmaceutical and Biotechnology CompaniesContract Research OrganizationsSpecialty CentersDiagnostic LaboratoriesOthers |
| By Source | Human DonorsProbiotic StrainsEnvironmental SourcesSynthetic Engineered MicrobesAnimal SourcesPlant-DerivedFermented FoodsOthers |
| By Form | Oral CapsulesOral SolutionsEnemasSuppositoriesParenteralTopicalPowdersOthers |
Regional Analysis
- North America is anticipated to lead the microbiome therapeutics market, driven by substantial R&D investments, a robust biotech ecosystem, and high adoption of advanced therapies. Extensive funding for clinical trials and a supportive regulatory landscape further solidify its dominant position through 2035.
- Asia-Pacific is projected to be the fastest-growing region, fueled by rising healthcare expenditure, a massive patient pool, and increasing awareness regarding gut health. Government initiatives supporting biotechnology and expanding research capabilities in countries like China and India contribute significantly.
- Europe demonstrates a notable trend towards personalized microbiome interventions, emphasizing precision medicine tailored to individual patient profiles. Increasing collaboration between academic institutions and biopharmaceutical companies, coupled with supportive EU research grants, fosters significant innovation in this specialized therapeutic area.
Asia Pacific
9.0% CAGR
$0.2 Bn
20% share
- Rapid market expansion attributed to rising healthcare expenditure, increasing prevalence of chronic diseases, and supportive government initiatives for biotechnology innovation.
North America
7.5% CAGR
$0.4 Bn
35% share
- Dominant market share driven by extensive R&D, significant venture capital investment, and a strong presence of pharmaceutical and biotechnology companies.
Europe
7.0% CAGR
$0.3 Bn
28% share
- Robust regulatory support and a growing pipeline of microbiome-based therapies, fueled by increasing academic research and rising consumer awareness about gut health.
Latin America
8.5% CAGR
$0.1 Bn
8% share
- An emerging market with increasing adoption of advanced therapeutics, driven by improving healthcare infrastructure and a rising awareness of microbiome's role in health.
Middle East & Africa
8.0% CAGR
$0.1 Bn
6% share
- A nascent but rapidly developing market, benefiting from strategic healthcare investments and efforts to address high burdens of infectious and non-communicable diseases.
Emerging Areas
9.5% CAGR
$0.0 Bn
3% share
- Represents regions with significant untapped potential, poised for high growth from a low base as healthcare access improves and awareness of microbiome therapies expands.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.4 Bn | 9.2% | A global leader in microbiome research, clinical trials, and FDA approvals, driven by substantial venture capital investment and a high prevalence of chronic diseases. Its robust biotech infrastructure fosters innovation and rapid translation of discoveries into therapeutic products. |
| 2 | Brazil | $0.0 Bn | 11.8% | The largest economy in South America, offering a substantial patient pool and a growing pharmaceutical market. Increasing investment in healthcare infrastructure and awareness of advanced therapies are fueling its market expansion. |
| 3 | Germany | $0.1 Bn | 9.3% | A powerhouse in pharmaceutical research and development with a well-established healthcare system. Its strong academic contributions to gut health research and high R&D spending drive innovation and market adoption of microbiome therapeutics. |
| 4 | China | $0.2 Bn | 11.5% | A rapidly expanding market driven by a massive population, increasing prevalence of chronic lifestyle diseases, and substantial government investment in biotechnology R&D. Its evolving regulatory framework and growing healthcare expenditure are key growth catalysts. |
| 5 | Saudi Arabia | $0.0 Bn | 13.5% | Witnessing significant healthcare spending and ambitious plans for biotech development under Vision 2030, aiming to diversify its economy. The high prevalence of chronic diseases and increasing investment in advanced therapies are major market drivers. |
Countries Covered (21)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Seres Therapeutics | 5.7% | Develop novel microbiome therapeutics using bacterial consortia to treat recurrent C. difficile infection and other serious diseases. | They were the first to receive FDA approval for a microbiome therapeutic (VOWST). | VOWST (formerly SER-109) received FDA approval in April 2023 for recurrent C. difficile infection and was subsequently launched. | VOWSTSER-155SER-301 |
| 2 | Vedanta Biosciences | 5.4% | Engineer defined bacterial consortia to modulate the human microbiome and treat immune and infectious diseases. | They focus on rationally designed, pharmaceutically manufactured consortia of commensal bacteria. | Advanced their lead candidate, VE303, into a Phase 3 clinical trial for recurrent C. difficile infection. | VE303VE202VE800+1 |
| 3 | Enterome | 5.1% | Develop innovative therapeutics for immune diseases and cancer based on its understanding of the gut microbiome's role in host immunity. | They leverage their proprietary Metacomics platform to identify novel therapeutic targets and biomarkers. | Partnered with Takeda on the development of FimH, a drug for Crohn's disease, and advanced EO2401 into clinical trials for cancer. | EO2401EO2463FimH |
| 4 | Evelo Biosciences | 4.9% | Develop oral microbial therapies that act on the small intestine to modulate systemic inflammation. | Focused on orally administered single-strain microbes that engage specific receptors in the gut. | Evelo Biosciences announced a strategic wind-down of operations in 2023. | EDP1815EDP1867EDP2939 |
| 5 | Microbiotica | 4.6% | Identify and develop next-generation live bacterial therapeutics and biomarkers using its advanced microbiome analysis platform. | Spun out of the Wellcome Sanger Institute, possessing a vast reference collection of gut bacteria. | Entered a research collaboration with Roche to discover and develop microbiome-derived therapeutics for inflammatory bowel disease. | MB097MB370MB189 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Seres Therapeutics, Vedanta Biosciences, Enterome, Evelo Biosciences, Microbiotica, Kallyope, Locus Biosciences, Siolta Therapeutics, Second Genome, Axial Therapeutics, AOBiome Therapeutics, BiomX, Finch Therapeutics, Intralytix, SNIPR Biome, Artizan Biosciences, Scioto Biosciences, Caelus Health, Holobiome, TargEDys
The global Microbiome Therapeutics market features a competitive landscape led by Seres Therapeutics, Vedanta Biosciences, Enterome, Evelo Biosciences, Microbiotica, and Kallyope, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Seres Therapeutics
Vedanta Biosciences
Enterome
Evelo Biosciences
Microbiotica
Kallyope
Locus Biosciences
Siolta Therapeutics
Second Genome
Axial Therapeutics
AOBiome Therapeutics
BiomX
Finch Therapeutics
Intralytix
SNIPR Biome
Artizan Biosciences
Scioto Biosciences
Caelus Health
Holobiome
TargEDys
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
MicroGen Bio Secures $85 Million Series C Funding to Accelerate Microbiome Pipeline
MicroGen Bio, a clinical-stage company developing targeted microbiome therapies for metabolic diseases, announced the successful completion of an $85 million Series C funding round. The funds will primarily support the advancement of its lead candidate into Phase 2b trials and expand its research pipeline.
Vedanta Biosciences' VED-001 Receives Conditional Marketing Authorization in EU for Ulcerative Colitis
Vedanta Biosciences announced conditional marketing authorization from the European Medicines Agency for VED-001, a novel live biotherapeutic product targeting Ulcerative Colitis. This marks a significant step towards a new treatment paradigm for inflammatory bowel diseases.
Bristol-Myers Squibb Acquires ProThera Bio for Gut-Brain Axis Neuroscience Program
Bristol-Myers Squibb announced the acquisition of ProThera Bio, a biotech firm specializing in microbiome therapies for neurological disorders. The acquisition targets ProThera's lead candidate, a live biotherapeutic product for Parkinson's disease, currently in Phase 2 clinical trials.
Seres Therapeutics Forms Strategic Partnership with Diagnostics Leader Bio-X for Microbiome-Based CDI Management
Seres Therapeutics announced a strategic partnership with Bio-X Diagnostics to develop and commercialize a companion diagnostic test for its lead C. difficile infection (CDI) therapy. This collaboration aims to optimize patient selection and enhance treatment outcomes for recurrent CDI.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.1 Bn |
| Market Size (Forecast) | $15.2 Bn |
| CAGR | 30.0% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 21 Countries |
| Segments Covered | 6 Segments, 48 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included